A pan-cancer analysis of the oncogenic role of Golgi transport 1B in human tumors.

BACKGROUND

Owing to the aggressiveness and treatment-refractory nature of cancer, ideal candidates for early diagnosis and treatment are needed. Golgi transport 1B () has been associated with cellular malignant behaviors and immune responses in colorectal and lung cancer, but a systematic pan-cancer analysis on has not been conducted.

METHODS

The expression status and clinical association of in The Cancer Genome Atlas (TCGA) were analyzed. Genetic and methylation alterations in were explored. The relationship between and immune cell infiltration was also investigated. Genes related to expression were selected and analyzed.

RESULTS

was highly expressed in most tumors, and there was a positive correlation between expression and clinical pathological parameters. High expression levels of have been associated with poor prognosis of most cancers. Copy number amplification was the primary type of genetic alterations, which was related to the prognosis of pan-cancer cases. There were different levels of promoter methylation across cancer types. The methylation level of the probe cg07371838 and cg25816357 was closely associated with prognosis in diverse cancers. There was also a positive correlation between genetic alterations and CD4+ T lymphocytes, especially the Th2 subset, as well as between expression and the estimated infiltration value of cancer-associated fibroblasts. Serine/threonine kinase receptor-associated protein (), integrator complex subunit 13 (), and ethanolamine kinase 1 () were the most relevant genes for expression, and their interactions with were involved in regulating the transforming growth factor (TGF)-β receptor signaling pathway and epithelial-mesenchymal transition (EMT).

CONCLUSIONS

This pan-cancer analysis provided a comprehensive understanding of the oncogenic role of , highlighting a potential mechanism whereby influences the tumor microenvironment, as well as cancer immunotherapy.